Impact of p-tau181 and p-tau217 levels on enrollment for randomized clinical trials and future use of anti-amyloid and anti-tau drugs

Expert Rev Neurother. 2020 Dec;20(12):1211-1213. doi: 10.1080/14737175.2020.1841637. Epub 2020 Dec 2.
No abstract available

Keywords: Alzheimer’s disease; Plasma biomarker; diagnosis; p-tau181; screening.

Publication types

  • Editorial
  • Research Support, Non-U.S. Gov't